The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Amgen
Research Funding - Merck (Inst)
Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.
 
Paul Nghiem
Honoraria - EMD Serono; Merck Sharp & Dohme
Consulting or Advisory Role - EMD Serono; Pfizer
Research Funding - Bristol-Myers Squibb; EMD Serono
Patents, Royalties, Other Intellectual Property - Patent pending for high affinity T cell receptors that target the Merkel polyomavirus.
 
Shailender Bhatia
Honoraria - EMD Serono; Genentech/Roche
Consulting or Advisory Role - EMD Serono; Genentech/Roche
Research Funding - Bristol-Myers Squibb (Inst); Conkwest (Inst); EMD Serono (Inst); Immune Design (Inst); Merck (Inst); NantWorks (Inst); OncoSec (Inst)
Travel, Accommodations, Expenses - EMD Serono; NantWorks
 
Evan J. Lipson
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Sysmex (Inst)
Patents, Royalties, Other Intellectual Property - METHOD OF PREVENTING ORGAN TRANSPLANT REJECTIONS USING AGONISTS TO THE PD-1 CHECKPOINT PATHWAY (Inst)
 
William Howard Sharfman
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst)
 
Ragini Reiney Kudchadkar
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Research Funding - Merck
 
Philip Adam Friedlander
Stock and Other Ownership Interests - allergan; Avalanche Biotechnologies; Bristol-Myers Squibb; Clovis Oncology; Incyte; Merrimack
Consulting or Advisory Role - Array BioPharma; Castle Biosciences; Genentech; Seagen
Travel, Accommodations, Expenses - Array BioPharma; Castle Biosciences; Seagen
 
Andrew Scott Brohl
Expert Testimony - GlaxoSmithKline (I)
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Genoptix; GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Harriet M. Kluger
Consulting or Advisory Role - Alexion Pharmaceuticals; Biodesix; Corvus Pharmaceuticals; Genentech/Roche; Nektar; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sunil A. Reddy
No Relationships to Disclose
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Travel, Accommodations, Expenses - Lilly
 
Brent Allen Hanks
Honoraria - Novartis; Virginia Oncology Associates
Consulting or Advisory Role - EMD Serono; G1 Therapeutics
Speakers' Bureau - CE Concepts
Research Funding - AstraZeneca; GlaxoSmithKline; Merck; OncoMed
Patents, Royalties, Other Intellectual Property - Inhibiting paracrine Wnt ligand signaling to augment checkpoint inhibitor immunotherapy. (Inst); Modulating the metabolism of dendritic cells to enhance anti-tumor immunity. (Inst)
 
Thomas Olencki
Research Funding - Bristol-Myers Squibb (Inst); Immunocore (Inst); Pfizer (Inst); Regeneron (Inst)
 
Brian C. Boulmay
No Relationships to Disclose
 
Lisa M Lundgren
No Relationships to Disclose
 
Nirasha Ramchurren
No Relationships to Disclose
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
 
Elad Sharon
No Relationships to Disclose
 
Martin A. Cheever
No Relationships to Disclose
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - Aduro Biotech (I); Compugen (I); DNAtrix (I); Five Prime Therapeutics; FLX Bio (I); Jounce Therapeutics (I); NexImmune (I); Potenza Therapeutics (I); Tizona Therapeutics, Inc. (I); WindMIL (I)
Consulting or Advisory Role - Abbvie; Amgen (I); Avidity Biosciences; Compugen (I); DNAtrix (I); Five Prime Therapeutics; FLX Bio (I); MedImmune (I); Merck (I); Pfizer (I); Potenza Therapeutics (I); Sanofi (I); Tizona Therapeutics, Inc. (I); WindMIL (I)
Research Funding - Bristol-Myers Squibb; Compugen (I); Potenza Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Aduro Biotech (I); Bristol-Myers Squibb (I); Potenza Therapeutics (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Five Prime Therapeutics